Abdullah Ağın1, Sibel Kocabeyoglu2, Aysun Yucel Gencoglu3, Sercan Aksoy4, Jale Karakaya5, Murat Irkec6. 1. Department of Ophthalmology, University of Health Sciences, Haseki Training and Research Hospital, Istanbul, Turkey. 2. Department of Ophthalmology, Hacettepe University School of Medicine, Ankara, Turkey. sibelkocabeyoglu@gmail.com. 3. Department of Ophthalmology, University of Health Sciences, Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey. 4. Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey. 5. Department of Biostatistics, Hacettepe University School of Medicine, Ankara, Turkey. 6. Private Practice, Ankara, Turkey.
Abstract
OBJECTIVES: To evaluate the ocular surface, meibomian glands and corneal structural changes using in vivo confocal microscopy (IVCM) in patients receiving aromatase inhibitor (AI) therapy due to the breast cancer. METHODS: This prospective observational study included 13 patients undergoing AI therapy. The patients were evaluated before the treatment, at 3- and 6-month timepoints of AI therapy. To examine the ocular surface and tear film, corneal sensitivity (CS) measurement with Cochet-Bonnet Aesthesiometer, tear film break-up time (TBUT), lissamine green (LG) staining, Schirmer I test with anaesthesia (ST) and the ocular-surface disease index (OSDI) questionnaire were performed consecutively. Corneal cell densities and sub-basal nerve plexus were evaluated with IVCM (ConfoScan 4, Nidek, Japan). Finally, quantitative MG drop-out assessment was made using infrared meibography. Shapiro Wilk, Friedman's and Post-hoc Dunn tests were used for the statistical analysis. RESULTS: TBUT, ST scores, basal epithelium, anterior and posterior keratocytes and endothelial cell densities, long and total sub-basal nerve densities were found to be decreased (p < 0.001, p = 0.023, p < 0.001, p = 0.01, p = 0.002, p = 0.004, p < 0.001, p < 0.001), and meiboscore, CS, OSDI scores and sub-basal nerve tortuosity values were increased (p < 0.001, p = 0.015, p = 0.001, p = 0.004) during the treatment. Endothelial pleomorphism rates were lower at the 3- and 6-month timepoints compared to before the treatment (p = 0.04). CONCLUSION: This study showed that aromatase inhibitor therapy causes deteriorations in many of the ocular-surface parameters and corneal structural changes in relation with the duration of treatment. These patients should be observed during the therapy in terms of the ocular-surface side effects.
OBJECTIVES: To evaluate the ocular surface, meibomian glands and corneal structural changes using in vivo confocal microscopy (IVCM) in patients receiving aromatase inhibitor (AI) therapy due to the breast cancer. METHODS: This prospective observational study included 13 patients undergoing AI therapy. The patients were evaluated before the treatment, at 3- and 6-month timepoints of AI therapy. To examine the ocular surface and tear film, corneal sensitivity (CS) measurement with Cochet-Bonnet Aesthesiometer, tear film break-up time (TBUT), lissamine green (LG) staining, Schirmer I test with anaesthesia (ST) and the ocular-surface disease index (OSDI) questionnaire were performed consecutively. Corneal cell densities and sub-basal nerve plexus were evaluated with IVCM (ConfoScan 4, Nidek, Japan). Finally, quantitative MG drop-out assessment was made using infrared meibography. Shapiro Wilk, Friedman's and Post-hoc Dunn tests were used for the statistical analysis. RESULTS: TBUT, ST scores, basal epithelium, anterior and posterior keratocytes and endothelial cell densities, long and total sub-basal nerve densities were found to be decreased (p < 0.001, p = 0.023, p < 0.001, p = 0.01, p = 0.002, p = 0.004, p < 0.001, p < 0.001), and meiboscore, CS, OSDI scores and sub-basal nerve tortuosity values were increased (p < 0.001, p = 0.015, p = 0.001, p = 0.004) during the treatment. Endothelial pleomorphism rates were lower at the 3- and 6-month timepoints compared to before the treatment (p = 0.04). CONCLUSION: This study showed that aromatase inhibitor therapy causes deteriorations in many of the ocular-surface parameters and corneal structural changes in relation with the duration of treatment. These patients should be observed during the therapy in terms of the ocular-surface side effects.
Authors: H Spelsberg; M Klueppel; T Reinhard; M Glaeser; D Niederacher; M W Beckmann; R Sundmacher Journal: Eye (Lond) Date: 2004-07 Impact factor: 3.775
Authors: Sharon J Elliot; Paola Catanuto; Diego G Espinosa-Heidmann; Pedro Fernandez; Eleut Hernandez; Peter Saloupis; Kenneth Korach; Michael Karl; Scott W Cousins Journal: Exp Eye Res Date: 2009-09-30 Impact factor: 3.467
Authors: D A Sullivan; E M Rocha; M D Ullman; K L Krenzer; J Gao; I Toda; M R Dana; D Bazzinotti; L A da Silveira; L A Wickham Journal: Adv Exp Med Biol Date: 1998 Impact factor: 2.622
Authors: Jack Cuzick; Ivana Sestak; John F Forbes; Mitch Dowsett; Jill Knox; Simon Cawthorn; Christobel Saunders; Nicola Roche; Robert E Mansel; Gunter von Minckwitz; Bernardo Bonanni; Tiina Palva; Anthony Howell Journal: Lancet Date: 2013-12-12 Impact factor: 79.321
Authors: Dragos Serban; Daniel Ovidiu Costea; Anca Zgura; Mihail Silviu Tudosie; Ana Maria Dascalu; Gabriel Andrei Gangura; Catalin Gabriel Smarandache; Alexandru Dan Sabau; Corneliu Tudor; Mihai Faur; Andreea Cristina Costea; Daniela Stana; Simona Andreea Balasescu; Laura Carina Tribus; Ciprian Tanasescu Journal: In Vivo Date: 2022 Jan-Feb Impact factor: 2.155